Compare Amphastar Pharmaceuticals Inc (AMPH) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs BlackRock TCP Capital Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.74 (market cap $826.08M), while BlackRock TCP Capital Corp trades at $3.24 (market cap $273.10M). The key difference: Amphastar Pharmaceuticals Inc is far larger — about 3× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 25.81% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | TCPC | |
|---|---|---|
Market Cap | $826.08M | $273.10M |
Sector | Health | Financials |
52-Week High | $30.81 | $7.90 |
52-Week Low | $16.87 | $3.14 |
Enterprise Value | $1.22B | — |
Dividend Yield | — | 25.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
TCPC trades at $3.26, up 3.16% today, but faces a bearish technical outlook with negative revenue and net income trends. The company reported a net loss of $88.93M for 2025 with revenue of -$77.27M, though it maintains a dividend yield above 10%. Recent news highlights potential dividend sustainability concerns and an ongoing legal investigation into corporate governance.
The outlook remains challenging with declining fundamentals and bearish technical signals. Investment opportunities exist for income-focused investors due to high dividend yield, but risks include persistent losses, legal scrutiny, and negative analyst sentiment with only 30.77% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
